Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations.
Takayuki Kondo; Haruhiko Banno; Taro Okunomiya; Yoko Amino; Kayoko Endo; Akiyoshi Nakakura; Ryuji Uozumi; Akemi Kinoshita; Harue Tada; Satoshi Morita; Hidehiro Ishikawa; Akihiro Shindo; Ken Yasuda; Yosuke Taruno; Takakuni Maki; Takashi Suehiro; Kohji Mori; Manabu Ikeda; Koji Fujita; Yuishin Izumi; Kazutomi Kanemaru; Kenji Ishii; Kazue Shigenobu; Yumiko Kutoku; Yoshihide Sunada; Shinobu Kawakatsu; Shunji Shiota; Toshifumi Watanabe; Osamu Uchikawa; Ryosuke Takahashi; Hidekazu Tomimoto; Haruhisa Inoue
BMJ open, 30 Jun. 2021, Peer-reviewed